MA28079A1 - Antagonistes de l'hormone concentrant la melanine - Google Patents

Antagonistes de l'hormone concentrant la melanine

Info

Publication number
MA28079A1
MA28079A1 MA28903A MA28903A MA28079A1 MA 28079 A1 MA28079 A1 MA 28079A1 MA 28903 A MA28903 A MA 28903A MA 28903 A MA28903 A MA 28903A MA 28079 A1 MA28079 A1 MA 28079A1
Authority
MA
Morocco
Prior art keywords
melanine
concentrating
hormone antagonists
units
taken together
Prior art date
Application number
MA28903A
Other languages
English (en)
Inventor
Xiufeng Eric Hu
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of MA28079A1 publication Critical patent/MA28079A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/79—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

vii) R3a et R3b ou R4a et R4b peuvent être pris conjointement pour former un motif répondant à la formule: C=X, dans laquelle X représente O,S ou NR5; et viii) deux motifs R3b ou deux motifs R4b provenant d'atomes de carbone adjacents peuvent être pris conjointement pour former une double liaison; les indices m et n ayant chacun indépendamment une valeur de 0 à 5.
MA28903A 2003-10-01 2006-03-31 Antagonistes de l'hormone concentrant la melanine MA28079A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50777303P 2003-10-01 2003-10-01
US53664004P 2004-01-15 2004-01-15

Publications (1)

Publication Number Publication Date
MA28079A1 true MA28079A1 (fr) 2006-08-01

Family

ID=34426018

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28903A MA28079A1 (fr) 2003-10-01 2006-03-31 Antagonistes de l'hormone concentrant la melanine

Country Status (20)

Country Link
US (1) US7304065B2 (fr)
EP (1) EP1667958A2 (fr)
JP (1) JP2007508303A (fr)
KR (1) KR20060060047A (fr)
CN (1) CN101068773A (fr)
AR (1) AR045958A1 (fr)
AU (1) AU2004278352B2 (fr)
BR (1) BRPI0415051A (fr)
CA (1) CA2540826A1 (fr)
CO (1) CO5690589A2 (fr)
IL (1) IL174370A0 (fr)
IS (1) IS8360A (fr)
MA (1) MA28079A1 (fr)
MX (1) MXPA06003654A (fr)
NO (1) NO20061953L (fr)
PE (1) PE20050475A1 (fr)
RU (1) RU2006110272A (fr)
SG (1) SG146692A1 (fr)
TW (1) TW200526554A (fr)
WO (1) WO2005033063A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008001160A1 (fr) * 2006-06-23 2008-01-03 The Procter & Gamble Company Antagonistes de l'hormone concentrant la mélanine
DK2041093T3 (da) * 2006-06-28 2010-08-02 Glaxo Group Ltd Til behandling af GPR38-receptor medierede sygdomme anvendelige piperazinylderivativer
US20100081825A1 (en) * 2006-10-06 2010-04-01 Taisho Pharmaceutical Co Ltd 1-naphthyl alkylpiperidine derivative
EP2213655A1 (fr) * 2007-04-27 2010-08-04 Paratek Pharmaceuticals, Inc. Procédés de purification de composés d'aminoalkyle de tétracycline
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
WO2009153720A1 (fr) * 2008-06-18 2009-12-23 Pfizer Limited Dérivés de nicotinamide
TW201040154A (en) 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted indanes, process for preparation thereof and use thereof as a medicament
AR075402A1 (es) * 2009-02-13 2011-03-30 Sanofi Aventis Derivados heterociclicos oxigenados y/o nitrogenados de tetrahidronaftaleno, medicamentos que los contienen y uso de los mismos en el tratamiento de trastornos metabolicos, tales como obesidad,entre otros.
WO2011083804A1 (fr) * 2010-01-06 2011-07-14 武田薬品工業株式会社 Dérivé d'indole

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206428A (en) 1989-11-16 1993-04-27 Tanabe Seiyaku Co., Ltd. Tetrahydronaphthalene derivatives and preparation thereof
ZA928276B (en) * 1991-10-31 1993-05-06 Daiichi Seiyaku Co Aromatic amidine derivates and salts thereof.
WO1994018204A1 (fr) * 1993-02-12 1994-08-18 Merck & Co., Inc. Antiarythmiques de classe iii a base de spiro (2h-1-benzopyranne-2, 4' piperidine)
WO1994027597A1 (fr) 1993-05-21 1994-12-08 Smithkline Beecham Corporation Acides imidazolyl-alcenoiques antagonistes du recepteur de l'angiotensine ii
AU2565595A (en) 1994-05-28 1995-12-21 Smithkline Beecham Plc Amide derivatives having 5ht1d-antagonist activity
DE4438029A1 (de) 1994-10-25 1996-05-02 Thomae Gmbh Dr K N.N-disubstituierte Benzocycloalkylamine, ihre Salze mit verträglichen organischen oder anorganischen Säuren, Verfahren zur Herstellung dieser Verbindungen und diese enthaltende Arzneimittel
AU5147196A (en) * 1995-03-27 1996-10-16 Smithkline Beecham Plc Bicyclic amine derivatives and their use as anti-psychotic a gents
DE19614718A1 (de) * 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
WO1998038156A1 (fr) 1997-02-27 1998-09-03 Takeda Chemical Industries, Ltd. Composes amines, leur elaboration, et leur utilisation comme inhibiteurs de la production d'amyloide beta
EP1104754A1 (fr) * 1998-08-11 2001-06-06 Daiichi Pharmaceutical Co., Ltd. Nouveaux derives sulfonyle
EP1218336A2 (fr) * 1999-09-20 2002-07-03 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
CA2407149C (fr) * 2000-04-28 2010-10-12 Takeda Chemical Industries, Ltd. Antagonistes de l'hormone concentrant la melanine
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
MXPA03005744A (es) 2000-12-22 2003-09-05 Schering Corp Antagonistas de piperidina mch y su uso en el tratamiento de obesidad.
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
EP1432693A2 (fr) 2001-10-01 2004-06-30 Taisho Pharmaceutical Co. Ltd. Antagonistes du recepteur de la mch
US7045636B2 (en) 2001-10-25 2006-05-16 Schering Corporation MCH antagonists for the treatment of obesity
CN1592739A (zh) 2001-11-26 2005-03-09 先灵公司 用于治疗肥胖和cns疾病的基于哌啶的mch拮抗剂
JP2005518365A (ja) 2001-11-27 2005-06-23 メルク　エンド　カムパニー　インコーポレーテッド ４−アミノキノリン化合物
CA2468015A1 (fr) 2001-11-27 2003-06-05 Merck & Co., Inc. Composes de 2-aminoquinoline
US7348328B2 (en) 2001-12-04 2008-03-25 Schering Corporation MCH antagonists for the treatment of obesity
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue Carbonsäureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
KR20050067419A (ko) 2002-10-21 2005-07-01 얀센 파마슈티카 엔.브이. 치환된 테트라린 및 인단으로의 ｘ 증후군의 치료
JP2006522825A (ja) * 2003-04-10 2006-10-05 アムジェン インコーポレイテッド ブラジキニンレセプター親和性を有する二環式化合物およびその薬学的組成物

Also Published As

Publication number Publication date
TW200526554A (en) 2005-08-16
KR20060060047A (ko) 2006-06-02
RU2006110272A (ru) 2007-11-10
PE20050475A1 (es) 2005-10-05
CA2540826A1 (fr) 2005-04-14
SG146692A1 (en) 2008-10-30
CO5690589A2 (es) 2006-10-31
EP1667958A2 (fr) 2006-06-14
AU2004278352A1 (en) 2005-04-14
CN101068773A (zh) 2007-11-07
IS8360A (is) 2006-03-17
US7304065B2 (en) 2007-12-04
WO2005033063A2 (fr) 2005-04-14
AU2004278352B2 (en) 2008-10-30
NO20061953L (no) 2006-06-13
WO2005033063A3 (fr) 2007-03-22
AR045958A1 (es) 2005-11-16
BRPI0415051A (pt) 2006-11-28
US20050075324A1 (en) 2005-04-07
MXPA06003654A (es) 2006-06-05
IL174370A0 (en) 2006-08-01
JP2007508303A (ja) 2007-04-05

Similar Documents

Publication Publication Date Title
MA28079A1 (fr) Antagonistes de l'hormone concentrant la melanine
USD502231S1 (en) Wave beam
USD488478S1 (en) Front face of a combined personal digital assistant and navigation device
WO2003035005A3 (fr) Heteroindanes: nouvelle classe de ligands cannabimimetiques efficaces
EP1502603A4 (fr) MEDICAMENT CONTENANT UNE COMPOSITION D'ANTICORPS APPROPRIEE AU PATIENT SOUFFRANT DE POLYMORPHISME FC gammma RIIIA
BR9916159A (pt) Sulfonamidas de hidróxi-difenil-uréia comoantagonistas dos receptores de il-8
WO2003004480A3 (fr) Piperazines et diazepanes substitues
EA200100797A1 (ru) Ацильные производные, используемые для лечения опосредованных vla-4 расстройств
CA2290745A1 (fr) Composes de carbamyloxy inhibant une adhesion de leucocytes regulee par vla-4
NO20043900L (no) Heterocykliske forbindelser som inhiberer leukocyttadhesjon formidlet av integriner
EA200401561A1 (ru) Гетероарильные соединения, которые ингибируют опосредованную 4-интегринами адгезию лейкоцитов
BR0313109A (pt) Ciclobuteno-1,2-dionas 3,4-dissubstituìdas como ligandos de receptor de quimiocina de cxc
DE60038449D1 (de) Arzneimittelwirkstoffe mit zwei kovalent verknüpften wirkstoffgruppen (natriumkanalblocker/p2y2 rezeptor agonist) zur behandlung von schleimhäuten
FR2849447B1 (fr) Procede de separation des aromatiques par distillation extractive et utilisation d'un solvant composite
WO2003039454A3 (fr) Inhibiteurs de la beta-secretase et leurs procede d'utilisation
WO2002008203A3 (fr) Derives de 3-(heteroaryl)alanine inhibiteurs de l'adherence des leucocytes provoquee par vla-4
ATE264298T1 (de) Alpha-aminoessigsäure derivate als alpha 4 beta 7-rezeptor antagonisten
BR9912010A (pt) Polimorfo de um produto farmacêutico
BR9812773A (pt) "alfa-amino-epsilon-caprolactamas policìclicas e compostos relacionados"
CL2004001068A1 (es) Compuestos derivados de 2,3,4,5-tetrahidrobenzo[f][1,4]oxazepina; procedimientos de preparacion; composicion farmaceutica que los contiene y su uso en la elaboracion de un medicamento util para el tratamiento de la enfermedad de alzheimer.
Yao et al. Potent P1′ biphenylmethyl substituted aggrecanase inhibitors
USD451053S1 (en) Combined walker and wheelchair
BR9807437A (pt) Anticorpos monoclonais gama-1 e gama-3 anti-humanos cd23 e sua utilização como terapêuticos
Sawa et al. Discovery of selective phosphonamide-based inhibitors of tumor necrosis factor-α converting enzyme (TACE)
EP1483580A4 (fr) Marqueur biologique indiquant l'efficacite des medicaments coupe-faim